- Supported exchanges /
- F /
- 6ML0.F
MOLECULAR PARTNERS ADS/1 (6ML0 F) stock market data APIs
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLECULAR PARTNERS ADS/1 Financial Data Overview
| 5.3 | |
| 5.5 | |
| - | |
| 5.7 | |
| 5.3 | |
| 3-10.6 | |
| 199 M | |
| 33 194 K | |
| 7 862 K | |
| 0.614 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
MOLECULAR PARTNERS ADS/1 Fundamental Data is available in our Financial Data APIs
- Net Revenue 7 862 K
- EBITDA -61 049 000
- Earnings Per Share -1.86
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get MOLECULAR PARTNERS ADS/1 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get MOLECULAR PARTNERS ADS/1 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
